Frazor Titus Edmondson III Sells 10,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Frazor Titus Edmondson III sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $21.33, for a total transaction of $213,300.00. Following the completion of the transaction, the insider now directly owns 16,408 shares of the company's stock, valued at approximately $349,982.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Frazor Titus Edmondson III also recently made the following trade(s):

• On Tuesday, April 2nd, Frazor Titus Edmondson III sold 885 shares of Zai Lab stock. The stock was sold at an average price of $16.15, for a total transaction of $14,292.75.

Zai Lab Trading Down 4.4 %

Shares of Zai Lab stock traded down $0.92 on Thursday, reaching $19.93. 565,835 shares of the stock were exchanged, compared to its average volume of 666,772. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $37.92. The business has a fifty day moving average price of $16.86 and a two-hundred day moving average price of $22.02. The firm has a market capitalization of $1.98 billion, a PE ratio of -5.74 and a beta of 1.11.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The business had revenue of $87.15 million for the quarter, compared to analyst estimates of $77.07 million. During the same period in the previous year, the business posted ($0.51) earnings per share. Research analysts expect that Zai Lab Limited will post -3.13 EPS for the current year.

Institutional Trading of Zai Lab

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Zai Lab by 68.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,371 shares of the company's stock worth $33,000 after buying an additional 557 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Zai Lab by 51.2% during the first quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company's stock worth $43,000 after buying an additional 904 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Zai Lab by 58.5% in the third quarter. PNC Financial Services Group Inc. now owns 1,896 shares of the company's stock valued at $46,000 after purchasing an additional 700 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Zai Lab in the first quarter worth $64,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Zai Lab by 1,923.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company's stock worth $70,000 after acquiring an additional 2,424 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Citigroup decreased their price objective on shares of Zai Lab from $123.00 to $66.00 and set a "buy" rating for the company in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zai Lab presently has an average rating of "Buy" and a consensus price target of $64.22.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.